Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Amgen
Amgen
AstraZeneca, Amgen Breathing Easier with Optimistic Phase III Asthma Drug Results
AstraZeneca, Amgen Breathing Easier with Optimistic Phase III Asthma Drug Results
BioSpace
AstraZeneca
Amgen
clinical trials
severe asthma
asthma
antibodies
Flag link:
Merck inks $1.9B Pandion takeover to square up against Amgen, Lilly and Roche
Merck inks $1.9B Pandion takeover to square up against Amgen, Lilly and Roche
Fierce Biotech
Merck
Pandion
M&A
immune modulators
Amgen
Eli Lilly
Roche
Flag link:
Amgen Submits Supplemental NDA for Mild-to-Moderate Psoriasis Drug Otezla
Amgen Submits Supplemental NDA for Mild-to-Moderate Psoriasis Drug Otezla
BioSpace
Amgen
Otezla
FDA
psoriasis
Flag link:
Treating COVID-19 long-haulers with Amgen's sleeper heart drug Corlanor
Treating COVID-19 long-haulers with Amgen's sleeper heart drug Corlanor
Fierce Biotech
Amgen
Corlanor
COVID-19
COVID-19 long haulers
Flag link:
Amgen loses appeal in patent suit against Sanofi/Regeneron’s Praluent. It’s a bummer for Bristol Myers Squibb and Merck, too
Amgen loses appeal in patent suit against Sanofi/Regeneron’s Praluent. It’s a bummer for Bristol Myers Squibb and Merck, too
Endpoints
Amgen
patents
Sanofi
Regeneron
Praluent
Repatha
Merck
Flag link:
Amgen cuts 'several hundred' U.S. jobs, primarily sales reps, as COVID-19 speeds a shift to digital
Amgen cuts 'several hundred' U.S. jobs, primarily sales reps, as COVID-19 speeds a shift to digital
Fierce Pharma
Amgen
drug reps
layoffs
pandemic
COVID-19
Flag link:
Amgen slams the brakes on a clutch of cancer drugs as reality BiTEs
Amgen slams the brakes on a clutch of cancer drugs as reality BiTEs
Fierce Biotech
Amgen
earnings
cancer
oncology
drug development
Flag link:
Amgen Slips Even After Earnings and Revenue Beat Estimates
Amgen Slips Even After Earnings and Revenue Beat Estimates
TheStreet.com
Amgen
earnings
Flag link:
Amgen study data bolster prospects of KRAS-blocking cancer drug
Amgen study data bolster prospects of KRAS-blocking cancer drug
BioPharma Dive
Amgen
sotorasib
clinical trials
KRAS mutation
cancer
Flag link:
10 key clinical trials to watch in the first half of 2021
10 key clinical trials to watch in the first half of 2021
BioPharma Dive
clinical trials
Novavax
AstraZeneca
JNJ
vaccines
COVID-19
Biomarin
Amgen
Merck
Pfizer
Roche
SAGE Therapeutics
Biogen
Vertex Pharmaceuticals
Flag link:
Amgen ponies up $240M for Michigan discovery outfit's dendritic cell-based molecules for autoimmune disorders
Amgen ponies up $240M for Michigan discovery outfit's dendritic cell-based molecules for autoimmune disorders
Endpoints
Amgen
autoimmune disease
Evoq Therapeutics
Flag link:
Lilly, Amgen and more back advocacy group's push to double migraine research dollars
Lilly, Amgen and more back advocacy group's push to double migraine research dollars
Fierce Pharma
Eli Lilly
Amgen
migraines
Allergan
Novartis
Biohaven
Teva Pharmaceutical
Flag link:
2021 Best Places to Work in Medical Sales
2021 Best Places to Work in Medical Sales
MedReps.com
devices
drug reps
Syneos Health
Teleflex
Avion Pharmaceuticals
Acella
Conmed
Acumed
Lundbeck
Amgen
Biogen
Spark Therapeutics
Flag link:
Amgen-AstraZeneca Experimental Asthma Drug Surprisingly Flops in Phase III
Amgen-AstraZeneca Experimental Asthma Drug Surprisingly Flops in Phase III
BioSpace
Amgen
AstraZeneca
asthma
clinical trials
tezepelumab
Flag link:
Amgen and Novartis tap TV host to jump-start migraine conversations—and fuel understanding
Amgen and Novartis tap TV host to jump-start migraine conversations—and fuel understanding
Fierce Pharma
Aimovig
Amgen
Novartis
migraines
celebrity endorsements
Flag link:
Could Amgen's Xgeva boost immunotherapy in breast cancer?
Could Amgen's Xgeva boost immunotherapy in breast cancer?
Fierce Biotech
Amgen
Xgeva
breast cancer
Flag link:
Vigil Neuroscience launches with a $50M Series A and two former Amgen neuroscience candidates
Vigil Neuroscience launches with a $50M Series A and two former Amgen neuroscience candidates
Endpoints
Vigil Neuroscience
funding
Amgen
Neurosciences
Flag link:
Amgen plans 2020 filing for FDA approval of KRAS drug sotorasib
Amgen plans 2020 filing for FDA approval of KRAS drug sotorasib
Fierce Biotech
Amgen
FDA
sotorasib
KRAS
Flag link:
Amgen, Takeda, UCB enroll first patient in Covid-19 global platform study
Amgen, Takeda, UCB enroll first patient in Covid-19 global platform study
Pharmaceutical Business Review
COVID-19
pandemic
clinical trials
Takeda
Amgen
UCB
COVID R&D Alliance
Flag link:
Amgen severs 14-year Cytokinetics partnership, bailing on omecamtiv after mixed PhIII results
Amgen severs 14-year Cytokinetics partnership, bailing on omecamtiv after mixed PhIII results
Endpoints
Amgen
Cytokinetics
omecamtiv
clinical trials
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »